Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer

[1]  M. Hessner,et al.  Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. , 2009, Blood.

[2]  C. Szczylik,et al.  Targeted therapy of renal cell cancer. , 2008, Current opinion in investigational drugs.

[3]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[4]  M. Neurath,et al.  Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25− T Cells1 , 2007, The Journal of Immunology.

[5]  C. Piccirillo,et al.  TGF‐β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets , 2007 .

[6]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[7]  C. Szczylik,et al.  Recent developments in renal cell cancer immunotherapy , 2007, Expert opinion on biological therapy.

[8]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[9]  C. Piccirillo,et al.  TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. , 2007, Journal of leukocyte biology.

[10]  M. Blute.  Sunitinib in patients with metastatic renal cell carcinoma , 2006 .

[11]  L. Lefrançois,et al.  The descent of memory T-cell subsets , 2006, Nature Reviews Immunology.

[12]  W. Suchorska,et al.  Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice , 2006, Clinical Cancer Research.

[13]  F. Chagnon,et al.  Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  T. Jang,et al.  Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine. , 2005, Life sciences.

[15]  A. Mackiewicz,et al.  Human cancer gene therapy with cytokine gene-modified cells , 2004, Expert opinion on biological therapy.

[16]  G. Sczakiel,et al.  Ki-67-directed antisense therapy in an orthotopic renal cell carcinoma model. , 2004, European urology.

[17]  A. Mackiewicz,et al.  Effect of cyclophosphamide on tumorogenesis of the IL-6 and Hyper-IL-6 gene modified murine melanoma cells , 2004 .

[18]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[19]  R. Ahmed,et al.  Similarities and differences in CD4+ and CD8+ effector and memory T cell generation , 2003, Nature Immunology.

[20]  H. Pircher,et al.  A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells , 2003 .

[21]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[22]  M. Manns,et al.  Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo , 2003, International journal of cancer.

[23]  H. Pircher,et al.  A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. , 2003, Cancer research.

[24]  D. Kowalczyk,et al.  Genetically modified dendritic cells – a new, promising cancer treatment strategy? , 2002, Expert opinion on biological therapy.

[25]  H. Pandha,et al.  Immunotherapeutic potential of whole tumour cells , 2002, Cancer Immunology, Immunotherapy.

[26]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[27]  F. Chagnon,et al.  Murine renal cell carcinoma: evaluation of a dendritic‐cell tumour vaccine , 2001, BJU international.

[28]  H. Ertl,et al.  Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. , 2001, Vaccine.

[29]  Sung-Soo Yoon,et al.  Behavior of Murine Renal Carcinoma Cells Grown in Ectopic or Orthotopic Sites in Syngeneic Mice , 2001, Tumor Biology.

[30]  P. Schirmacher,et al.  The designer cytokine hyper-IL-6 mediates growth inhibition and GM–CSF-dependent rejection of B16 melanoma cells , 2001, Oncogene.

[31]  D. Kowalczyk,et al.  IL-6 and GM-CSF in tumor rejection model of renal cell cancer. , 2001, Advances in experimental medicine and biology.

[32]  G. Dranoff,et al.  Cytokine-secreting tumor cell vaccines. , 2000, Current opinion in immunology.

[33]  J. Nordstrom,et al.  Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma. , 2000, Human gene therapy.

[34]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[35]  R. Rees,et al.  Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. , 2000, Cancer research.

[36]  M. Micallef,et al.  Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration , 1999, Cancer Gene Therapy.

[37]  Alamdari,et al.  Follow‐up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy , 1999, BJU international.

[38]  W. Linehan,et al.  Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. , 1999, The Journal of urology.

[39]  F. Zimmermann,et al.  Tribromoethanol (Avertin) as an anaesthetic in mice , 1999, Laboratory animals.

[40]  P. Fayers,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial , 1999 .

[41]  Gareth Griffiths,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.

[42]  B. Chain,et al.  In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Rose-John,et al.  In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. , 1998, Journal of immunology.

[44]  C. Dinney,et al.  Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. , 1998, The Journal of urology.

[45]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[46]  M. Fukushima,et al.  Life prolonging effect of antitumor agents on postoperative adjuvant therapy in the lung spontaneous metastasis model in mice. , 1998, Anticancer research.

[47]  G. Haas,et al.  Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[49]  Y. Chernajovsky,et al.  Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model. , 1996, Cellular and molecular biology.

[50]  E. Gilboa,et al.  An experimental model simulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer , 1994, The Prostate.

[51]  J. Finke,et al.  Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2. , 1994, The American journal of pathology.

[52]  C. Logothetis,et al.  Surgery following response to interferon-α-based therapy for residual renal cell carcinoma , 1993 .

[53]  C. Logothetis,et al.  Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. , 1993, The Journal of urology.

[54]  P. Heinrich,et al.  Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. , 1992, Journal of immunology.

[55]  A. Porgador,et al.  Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.

[56]  T. Back,et al.  Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. , 1987, Journal of immunology.

[57]  M. H. Tan,et al.  Murine colon adenocarcinoma: syngeneic orthotopic transplantation and subsequent hepatic metastases. , 1977, Journal of the National Cancer Institute.

[58]  CANCER of the kidney and ureter. , 1953, Cancer bulletin.